Status: Recruiting
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and multiple myeloma.
Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: GI Cell, Inc.Updated: Jul 9, 2024Locations: 4
Eligibility criteria
At least 19 years of age [+6]
Clinically significant cardiovascular disease within 24 weeks [+17]